Interstitial lung diseases in collagen vascular diseases

European Respiratory Journal, Supplement

Volumn 18, Issue 32, 2001, Pages

  Lamblin, C ^a   Bergoin, C ^a   Saelens, T ^a   Wallaert, B ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Collagen vascular diseases; Fibrosis; Lung; Polymyositis; Rheumatoid arthritis; Scleroderma

Indexed keywords

AZATHIOPRINE; CHLORAMBUCIL; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOSTATIC AGENT; METHOTREXATE; PENICILLAMINE;

CLINICAL FEATURE; COLLAGEN DISEASE; DERMATOMYOSITIS; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; HISTOLOGY; HUMAN; INTERSTITIAL LUNG DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RHEUMATOID ARTHRITIS; SCLERODERMA; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULAR DISEASE; DIFFERENTIAL DIAGNOSIS; MIXED CONNECTIVE TISSUE DISEASE; SYSTEMIC SCLEROSIS;

ARTHRITIS, RHEUMATOID; COLLAGEN DISEASES; DERMATOMYOSITIS; DIAGNOSIS, DIFFERENTIAL; HUMAN; LUNG DISEASES, INTERSTITIAL; MIXED CONNECTIVE TISSUE DISEASE; SCLERODERMA, SYSTEMIC; VASCULAR DISEASES;

EID: 0035464548     PISSN: 09041850     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (147)

1. Pulmonary involvement in the collagen vascular diseases
2. The interstitial lung diseases associated with the collagen vascular disorders
3. Pulmonary scleroderma
4. Pathologic observations in systemic sclerosis
5. Pulmonary involvement in systemic sclerosis (scleroderma)
6. Interstitial lung disease in progressive systemic sclerosis: High-resolution CT versus radiography
7. Pulmonary involvement in progressive systemic sclerosis: Sequential evaluation with high-resolution CT, pulmonary function tests and bronchoalveolar lavage
8. Cardiorespiratory responses to incremental exercise in patients with systemic sclerosis
9. Fibrosing alveolitis in systemic sclerosis: Indices of lung function in relation to extent of disease on computed tomography
10. Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis
11. Pulmonary involvement in systemic sclerosis: The detection of early changes by thin section CT scan, bronchoalveolar lavage and 99mTc-DTPA clearance
12. Structural features of interstitial lung disease in systemic sclerosis
13. Pulmonary fibrosis in generalized scleroderma
14. Pulmonary vascular changes in scleroderma
15. Pulmonary arterial histology and morphometry in systemic sclerosis: A case-control autopsy study
16. Histopathologic subgroups in patients with fibrosing alveolitis associated with systemic sclerosis
17. Measurement and characterisation of circulating anti-endothelial cell IgG in connective tissue diseases
18. Endothelial injury in scleroderma. A protease mechanism
19. Endothelin, an endothelial-dependent vasoconstrictor in scleroderma
20. Localization of collagen mRNA in normal and scleroderma skin by in situ hybridization
21. Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis
22. Immunohistologic demonstration of platelet-derived growth factor (PDGF) and cis-oncogene expression in scleroderma
23. Local immune complexes and inflammatory response in patients with chronic interstitial pulmonary disorders associated with collagen vascular diseases
24. Interstitial lung disease in scleroderma: Immune complexes in sera and bronchoalveolar lavage fluid
25. Interstitial lung disease in scleroderma
26. Alveolar macrophage dysfunctions in collagen vascular diseases
27. Activated alveolar macrophages in subclinical pulmo-nary inflammation in collagen vascular diseases
28. Lung involvement in scleroderma
29. Lung inflammation in scleroderma: Clinical, radiographic, physiologic and cytopathological features
30. Evidence for chronic inflammation as a component of the interstitial lung disease associated with progressive systemic sclerosis
31. Role of inflammation in the lung disease of systemic sclerosis: Comparison with idiopathic pulmonary fibrosis
32. Bronchoalveolar lavage analysis of interstitial lung disease in CREST syndrome
33. Subclinical pulmonary involvement in collagen vascular diseases assessed by bronchoalveolar lavage. Relationship between alveolitis and subsequent changes in lung function
34. Subclinical alveolitis in immunological systemic disorders. Transition between health and disease?
35. Phagocyte enzymes in bronchoalveolar lavage from patients with pulmonary sarcoidosis and collagen vascular disorders
36. Clinical and subclinical alveolitis in collagen vascular diseases. Contribution of alpha-2 macroglobulin levels in BAL fluids
37. Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis
38. Pulmonary fibroblast expression of interleukin-8: A model for alveolar macrophage-derived cytokine networkinga model for alveolar macrophage-derived cytokine networking
39. Adhesion receptors of the immune system
40. Expression of chemokines interleukin-8 (IL-8), RANTES, and macrophage inhibitory factor-1 (MIP-1) in bronchoalveolar lavage fluid of patients with systemic sclerosis (SSc)
41. Increased expression of interleukin-8 gene by alveolar macrophages in idiopathic pulmonary fibrosis: A potential mechanism for the recruitment and activation of neutrophils in lung fibrosis
42. Interleukin-8. Differential expression in lone fibrosing alveolitis and systemic sclerosis
43. Recombinant human tumor necrosis factor-a: Effects on proliferation of normal and transformed cells in vitro
44. Growth and characterization of fibroblasts obtained from bronchoalveolar lavage of scleroderma patients
45. Fibrogenic cytokines: The role of immune mediators in the development of scar tissue
46. Mast cells' contribution to the fibrosing alveolitis of the scleroderma lung
47. Assessment and management of scleroderma lung disease
48. Colchicine suppresses the release of fibroblast growth factors from alveolar macrophages in vitro
49. The effect of D-Penicillamine on pulmonary findings in systemic sclerosis
50. D-Penicillamine therapy and interstitial lung disease in scleroderma
51. Immunosuppression with chlorambucil, versus placebo, for scleroderma
52. Cyclophosphamide and lowdose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease
53. Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma
54. Cyclosporine in systemic sclerosis. Results of a forty-eight-week open safety study in ten patients
55. Organizing diffuse alveolar damage associated with progressive systemic sclerosis
56. Rheumatoid disease with joint and pulmonary manifestations
57. Interstitial rheumatoid lung disease: A reassessment and review of the literature
58. Rheumatoid interstitial lung disease
59. Pulmonary dysfunction in rheumatoid disease
60. Pulmonary involvement in rheumatoid arthritis
61. Pulmonary manifestations of rheumatoid disease
62. Diffuse interstitial pulmonary fibrosis and rheumatoid arthritis
63. The extraarticular features of rheumatoid arthritis: A systematic analysis of 127 cases
64. Alpha- 1-antitrypsin phenotypes in fibrosing alveolitis and rheumatoid arthritis
65. Alpha-1-antitrypsin phenotypes, including M subtypes, in pulmonary disease associated with rheumatoid arthritis and systemic sclerosis
66. Lung biopsy in rheumatoid arthritis
67. Computed tomography of the pulmonary parenchyma. Part 2: Interstitial disease
68. High resolution computed tomography of the lungs in patients with RA and interstitial lung disease
69. Airway involvement in rheumatoid arthritis: Clinical, functional and HRCT findings
70. Interstitial lung disease in rheumatoid arthritis. Assessment with high resolution computed tomography
71. Clinical and histologic spectrum of bronchiolitis obliterans including bronchiolitis obliterans organizing pneumonia
72. Follicular bronchitis/bronchiolitis
73. Bronchoalveolar lavage: A sensitive tool for early diagnosis of pulmonary involvement in rheumatoid arthritis
74. Bronchoalveolar lavage fluid evaluation in rheumatoid arthritis
75. Lower respiratory tract abnormalities in rheumatoid interstitial lung disease: Potential role of neutrophils in lung injury
76. Increased TNF-α secretion by alveolar macrophages from patients with rheumatoid arthritis
77. Subclinical alveolar inflammation in rheumatoid arthritis: Superoxide anion, neutrophil chemotactic activity and fibronectin generation by alveolar macrophages
78. Neutrophil collagenase in rheumatoid interstitial lung disease
79. Bronchoalveolar lavage in patients with mild and severe rheumatoid lung disease
80. Elevated BAL fluid hista-mine levels and parenchymal pulmonary disease in rheumatoid arthritis
81. The interstitial lung disease associated with rheumatoid arthritis: Evidence for imbalance of helper T-lymphocyte subpopulations at sites of disease activity
82. Prediction of interstitial lung involvement in rheumatoid arthritis: The value of clinical data, chest roentgenogram, lung function and serologic parameters
83. Pulmonary fibrosis in rheumatoid arthritis: A review of clinical features and therapy
84. Interstitial pulmonary fibrosis with and without associated collagen vascular disease: Results of a two year follow up
85. Poor prognosis in patients with rheumatoid arthritis hospitalized for interstitial lung fibrosis
86. The lungs in rheumatoid arthritis
87. Patients with collagen vascular disease and dyspnea: The value of gallium scanning and bronchoalveolar lavage in predicting response to steroid therapy and clinical outcome
88. Diffuse interstitial pulmonary fibrosis associated with rheumatoid arthritis
89. Rheumatoid lung disease
90. Response to methotrexate in fibrosing alveolitis associated with connective tissue disease
91. Interstitial pneumonitis complicating rheumatoid arthritis: Sustained remission with azathioprine therapy
92. Successful use of cyclosporin for the treatment of aggressive pulmonary fibrosis in a patient with rheumatoid arthritis
93. Cryptogenic organising pneumonitis
94. Bronchiolitis obliterans organizing pneumonia
95. Clinical features of BOOP in Japan
96. Bronchiolitis obliterans organizing pneumonia and rheumatoid arthritis
97. Rheumatoid arthritis and cryptogenic organizing pneumonitis
98. Pulmonary lesions and rheumatoid arthritis
99. Pulmonary necrobiotic nodules as a presenting feature of rheumatoid arthritis
100. The association of cryoglobulinemia with nodules, vasculitis and fibrosing alveolitis in rheumatoid arthritis and their relationship to serum C1q binding activity and rheumatoid factor
101. Immunological and immunohistochemical analysis of rheumatoid nodules
102. Certain radiological appearances in the chest of coal miners suffering from rheumatoid arthritis
103. Pathological studies of modified pneumoconiosis in coal-miners with rheumatoid arthritis (Caplan's syndrome)
104. Pulmonary manifestations of systemic lupus erythematosus: Review of twelve cases of acute lupus pneumonitis
105. Pulmonary hemorrhage in systemic lupus erythematosus
106. The natural history of systemic lupus erythematosus by prospective analysis
107. The pulmonary manifestations of disseminated lupus erythematosus
108. Immunopathologic studies of pneumonitis in systemic lupus erythematosus
109. Alveolar macrophage dysfunction in systemic lupus erythematosus
110. Bronchoalveolar lavage cell analysis and lung function impairment in patients with systemic lupus erythematosus (SLE)
111. Increased nitric oxide in exhaled air of patients with systemic lupus erythematosus
112. Respiratory involve-ment in systemic lupus erythematosus: A clinical and immunological study
113. Lupus lung
114. Interstitial pneumonitis in association with polymyositis and dermatomyositis
115. Polymyositis and diffuse interstitial lung disease
116. Pulmonary involvement in polymyositis and dermatomyositis: Sequential evaluation with CT
117. Use of sequential DTPA clearance and high resolution computerized tomography in monitoring interstitial lung disease in dermatomyositis
118. Exercise limitation in patients with polymyositis
119. The precipitating antibody to an acidic nuclear protein antigen, the J0-1, in connective tissue disease. A marker for a subset of polymyositis with interstitial pulmonary fibrosis
120. Anti-J0-1 antibody: A marker for myositis with interstitial lung disease
121. Interstitial lung disease in polymyositis and dermatomyositis
122. Clinicopathological studies on interstitial lung disease in polymyositis-dermatomyositis
123. Interstitial lung disease in polymyositis and dermatomyositis: Analysis six cases and review of the literature
124. Atteinte pulmonaire des dermatoploymyosites. Intérêt du lavage bronchoalvéolaire
125. Treatment of dermatopolymyositis with methotrexate
126. Dermatopolymyositis with fibrosing alveolitis: Response to treatment with cyclophosphamide
127. Dermatomyositis with lung involvement, successfully treated with azathioprine
128. High single dose alternate day therapy regimens in treatment of polymyositis
129. Dermatopolymyosite et fibrose pulmonaire associées à un syndrome de Gougerot-Sjögren. Etude de 3 observations
130. The clinical role of bronchoalveolar lavage in collagen vascular diseases
131. Prognostic factors in polymyositis/dermatomyositis. A computer-assisted analysis of ninety-two cases
132. Pulmonary manifestations of Sjögren's syndrome
133. Pulmonary function abnormalities in Sjögren's syndrome and the sicca complex
134. Intertstitial lung disease in primary Sjögren's syndrome: Clinical pathological evaluation and response to treatment
135. Diseases of the small airways
136. Subclinical lung inflammation in primary Sjögren's syndrome
137. Lymphocyte subpopulations in bronchoalveolar lavage in Sjögren's syndrome. Evidence for an expansion of cytotoxic/suppressor subset in patients with alveolar neutrophilia
138. Alveolitis correlates with pulmonary involvement in primary Sjögren's syndrome
139. Interleukin-2 defect in the peripheral blood and the lung in patients with Sjögrens syndrome
140. Benign lymphoid disorders of the lungs with a theory regarding their development
141. Lymphoid interstitial pneumonia: Clinicopathological and immunopathological findings in 18 cases
142. Pulmonary findings in patients with primary Sjögren's syndrome
143. Pleuropulmonary abnormalities in primary Sjögren's syndrome
144. A prospective evaluation emphasizing pulmonary involvement in patients with mixed connective tissue disease
145. Pulmonary manifestations in mixed connective tissue disease
146. Severe pulmonary involvement in mixed connective tissue disease
147. Mixed connective tissue disease